Gamma oscillations in patients with parkinson's disease using chronic invasive brain recording: detection, entrainment, and functional relevance
Ended Project Grant Awarded Last action
- Award ID
- F31NS131043
- Recipient
-
The Regents Of The University Of California. San Francisco UEI KMH5K9V7S518
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $140,690
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Place of performance
- San Francisco, CA 94143, USA
Award details come from USAspending.gov.
Description
- Abstract
- As parkinson's disease (PD) progresses, patients develop slowness of movement (bradykinesia), tremor and rigidity. The first-line treatment for PD is the dopamine precursor levodopa. However, long-term use can lead to excessive movement (dyskinesia). To address levodopa-induced dyskinesia, medication dose is adjusted, and deep brain stimulation (DBS) of the basal ganglia is utilized. Without sufficiently lowering the medication dose, DBS can exacerbate dyskinesia. However, the mechanisms with which DBS causes dyskinesia, and how they are modulated by the dopaminergic cycle, are not fully understood. Excessive gamma band (65-90HZ) synchronization in the motor network correlates with dyskinesia in preliminary human studies. This signal has the potential to predict the onset of a dyskinetic episode when identified across a complete set of spectral features with continuous measures of motor fluctuations. During therapeutic DBS of either the subthalamic nucleus (STN) or globus pallidus (GP), the gamma oscillation is often entrained (amplified and modulated) to one-half the stimulation frequency. However, the clinical relevance of entrainment, and how IT may interact with across stimulation settings, has not yet been investigated. We predict that stimulation-induced 1:2 entrainment of cortical oscillations (oscillations detected at one-half the stimulation frequency) will therapeutically increase movement, while simultaneously decreasing excessive/pathological movement, otherwise known as dyskinesia. The goals of this study are to use multisite, chronically implanted neurostimulators and continuous wrist-wearable sensors to identify correlates of dyskinesia across a complete set of spectral features and to assess the possible clinical benefit, as IT relates to dyskinesia scores measured by the wearable sensors, of stimulation-induced entrainment of these spectral features. First, we will characterize correlates of dyskinesia using hundreds of hours of chronic neural recordings collected in a naturalistic environment across typical dopaminergic cycles with objective dyskinesia monitoring using wearables prior to the initialization of stimulation. The majority of these patients experience dyskinetic motor signs while taking their clinically recommended medications. Then, we will determine the most predictive features of dyskinesia using machine learning models to predict the continuous dyskinesia scores derived from validated wearable algorithms of the sensors worn on the wrist. We hypothesize that periodic gamma components will be most predictive of dyskinetic episodes prior to the onset of stimulation. Next, we will determine the relationship between gamma entrainment, dyskinesia severity, and deep brain stimulation amplitude. To do this, we will record neural data in a similar setting as before. However, during this process, patients will experience deep brain stimulation at the clinically recommended stimulation frequency, and patients will slowly increase their stimulation amplitude across a period of several weeks up to the clinically recommended setting. We hypothesize that gamma entrainment and dyskinesia severity will be inversely correlated at moderate levels of entrainment.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | -$38,866 | |
| Amendment | $44,889 | |
| Amendment | $44,889 | |
| Amendment | $0 | |
| Amendment | $44,889 | |
| Amendment | $0 | |
| Amendment | $44,889 | |
| Original award | $0 |
Quick answers
Who received award F31NS131043?
F31NS131043 was awarded to The Regents Of The University Of California. San Francisco by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on December 10, 2024.
How much is award F31NS131043 worth?
$140,690 has been obligated on F31NS131043.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award